Osilodrostat

Research use only, not for human use.

Osilodrostat (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).

Osilodrostat (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).

——

Animal Model:Male Ang-II- and ACTH-stimulated Sprague Dawley rats Dosage:0.1, 0.3, 1 and 3 mg/kg (Ang-II-stimulated rats) and 1, 3, 10, 30 and 100 mg/kg (ACTH-stimulated rats) Administration:Oral administration; once Result:Inhibited the increase in plasma aldosterone concentrations stimulated by Ang II or ACTH in a dose-dependent manner.Animal Model:dTG rats Dosage:3, 10, 30 and 100 mg/kg Administration:Oral administration; daily, for 52 weeks Result:Increased fractional LV (systolic and diastolic) shortening, normalized LV isovolumic relaxation time to RR (IVRT/RR) ratio and myocardial cell size and reduced LV weight in a dose-dependent manner.

LCI699

Metabolic Enzyme/Protease

MAO

11β-hydroxylase,aldosterone synthase

Endocrinology

——

928134-65-0

227.24

C13H10FN3

>98% (HPLC)

DMSO : ≥ 83.3 mg/mL; 366.57 mM

Fc1cc(ccc1[C@H]1CCc2cncn12)C#N

——

(-20℃)

With Ice Pack

≥ 2 years